Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
about
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaPharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.Luseogliflozin for the treatment of type 2 diabetes.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study.Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.Luseogliflozin: First Global Approval
P2860
Q34470786-BD1B210D-C710-451C-BC8F-55D8786D658DQ35558413-0459AD10-2B69-413F-946D-285477BD4620Q35666237-E6A93A37-655E-4087-954A-BD346E5CDDC5Q36131466-B1E117DC-1F50-4B1D-BADB-6DEC42D17328Q38264051-5FE177E5-0F87-4DEC-B3EC-5BFAED63C21FQ38389823-2DFF22EE-E827-4B3C-97F7-81E3E9A43C09Q38662950-E0C70619-C3AD-41B0-A4CA-0EA30C2019E4Q38908779-E96AACE2-306E-46FE-957D-BEEED9FAE074Q46650678-C8404CDC-8A91-4458-BB65-BF7B1108D398Q50266611-9D9E6BAC-56A5-41D7-ADDC-B15122116C05Q50509031-B9EE8680-7388-4E95-8E4E-7E3A8255A035Q51679305-99B01F82-E8BA-4B38-843F-08578AC5DC1EQ51692185-A9F9C6F1-EDDD-4D55-866C-C92C13CEAC20Q57485821-A1AC1107-79E4-4DF1-BE5D-1AFAB01FEC1C
P2860
Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety, pharmacokinetics, and ...... ind, placebo-controlled trial.
@en
Safety, pharmacokinetics, and ...... ind, placebo-controlled trial.
@nl
type
label
Safety, pharmacokinetics, and ...... ind, placebo-controlled trial.
@en
Safety, pharmacokinetics, and ...... ind, placebo-controlled trial.
@nl
prefLabel
Safety, pharmacokinetics, and ...... ind, placebo-controlled trial.
@en
Safety, pharmacokinetics, and ...... ind, placebo-controlled trial.
@nl
P2093
P2860
P1433
P1476
Safety, pharmacokinetics, and ...... lind, placebo-controlled trial
@en
P2093
Atsushi Fukatsu
Soichi Sakai
Yoshishige Samukawa
Yutaka Seino
P2860
P2888
P304
P356
10.1007/S12325-014-0102-3
P407
P577
2014-02-18T00:00:00Z